Peripheral arterial disease (PAD) results from the systemic atherosclerotic process. In this study, we aimed to determine the relationship between plasma atherogenic index (AIP), a ratio of molar concentrations of triglycerides to HDL-cholesterol, and long-term outcomes after endovascular therapy (EVT) in patients with superficial femoral artery (SFA) stenosis.
Methods
We retrospectively evaluated 673 patients who underwent EVT for PAD in our tertiary center between January 2015 and December 2020. In the receiver operating characteristic (ROC) curve analysis, the AIP value with the optimum cutoff value was determined as 0.576 to detect the presence of major adverse limb events (MALEs). Patients were divided into two groups according to low AIP (<0.576 as group 1) and high AIP (>0.576 as group 2).
Results
Among the major endpoints, long-term restenosis rates were significantly higher in patients in the high-AIP group than in the low-AIP group (p<.001). The lower extremity amputation rate was not statistically significant between the two groups. All-cause mortality rate (54 (31.6) versus 117 (68.4), p<.001) was significantly higher in patients in the high-AIP group than in the low-AIP group. In addition, the MALE rate (94 (29.2) versus 218 (62.1), p<.001) was significantly higher in patients in the high-AIP group than in those in the low-AIP group.
Conclusions
In conclusion, we found that AIP is a significant independent predictor of long-term MALE in patients who underwent EVT for SFA.
AboyansVRiccoJBBartelinkMEL, et al.2017ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European society for vascular surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Eur Heart J2018; 39: 763–816.
2.
FowkesFGRudanDRudanI, et al.Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet2013; 382: 1329–1340.
ShenSLuYQiH, et al.Association between ideal cardiovascular health and the atherogenic index of plasma. Medicine (Baltim)2016; 95(24): e3866.
8.
DobiásováMFrohlichJ. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin Biochem2001; 34(7): 583–588.
9.
NorgrenLHiattWRDormandyJA, et al.Inter-society consensus for the management of peripheral arterial disease (TASC-II). J Vasc Surg2007; 45(Suppl. S): 65–67.
10.
LammerJZellerTHauseggerKA, et al.Sustained benefit at 2 years for covered stents versus bare-metal stents in long SFA lesions: the VIASTAR trial. Cardiovasc Intervent Radiol2015; 38: 25–32.
11.
ScheinertDWernerMScheinertS, et al.Treatment of complex atherosclerotic popliteal artery disease with a new self-expanding interwoven nitinol stent: 12-month results of the Leipzig SUPERA popliteal artery stent registry. JACC Cardiovasc Interv2013; 6: 65–71.
12.
DotterCTJudkinsMP. Transluminal treatment of arteriosclerotic obstruction: description of a new technic and a preliminary report of its application. Circulation1964; 30(5): 654–670.
13.
MillerAJTakahashiEAHarmsenWS, et al.Treatment of superficial femoral artery restenosis. J Vasc Intervent Radiol2017; 28(12): 1681–1686.
14.
HessCNWangTYFuW, et al.Long-term outcomes and associations with major adverse limb events after peripheral artery revascularization. J Am Coll Cardiol2020; 75(5): 498–508.
15.
AnandSSCaronFEikelboomJW, et al.Major adverse limb events and mortality in patients with peripheral artery disease. J Am Coll Cardiol2018; 71(20): 2306–2315.
16.
Jung-JooneCJong-YounKHyoeunK, et al.Long-term clinical outcomes and prognostic factors after endovascular treatment in patients with chronic limb threatening Ischemia. Korean Circ J2022; 52(6): 429–440.
17.
HartleyLIgbinedionEHolmesJ, et al.Increased consumption of fruit and vegetables for the primary prevention of cardiovascular diseases. Cochrane Database Syst Rev2013; 6: CD009874.
18.
PuriRNissenSEShaoM, et al.Non-HDL cholesterol and triglycerides: implications for coronary atheroma progression and clinical events. Arterioscler Thromb Vasc Biol2016; 36: 2220–2228.
19.
CuchelMRaderDJ. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis?Circulation2006; 113: 2548–2555.
20.
OkamuraTHayakawaTKadowakiT, et al.NIPPON DATA90 research group. the inverse relationship between serum high-density lipoprotein cholesterol level and all-cause mortality in a 9.6-year followup study in the Japanese general population. Atherosclerosis2006; 184: 143–150.
21.
CalabresiLGomaraschiMFranceschiniG. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol2003; 23: 1724–1731.
22.
TanrıverdiBSavas TetikS. Pathophysiology of the atherosclerosis and risk factors. Marmara Pharm J2017; 21: 1–9.
23.
SalazarMRCarbajalHAEspecheWG, et al.Relation among the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio, insulin resistance, and associated cardio-metabolic risk factors in men and women. Am J Cardiol2012; 109: 1749–1753.
24.
DobiásováMFrohlichJSedováM, et al.Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res2011; 52(3): 566–571.
25.
OnatACanGKayaH, et al.therogenic index of plasma” (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. J Clin Lipidol2010; 4(2): 89–98.
26.
AykanAC¸HatemEKarabayCY, et al.Complexity of lower extremity peripheral artery disease reflects the complexity of coronary artery disease. Vascular2015; 23: 366–373.
27.
YiqiangZJinmingYRongjingD, et al.Triglyceride to high density lipoprotein cholesterol ratio, total cholesterol to high density lipoprotein cholesterol ratio and low ankle brachial index in an elderly population. Vasa2014; 43(3): 189–197. DOI: 10.1024/0301-1526/a000348.
28.
EnginMAydınCGuvencO. Is it possible to predict the complexity of peripheral artery disease with atherogenic index?vascular2020; 28(5): 513–519. Doi: 10.1177/1708538120923531.
29.
Jiang-HuaWYu-YuZZhi-GangW, et al.Triglyceride to HDL-C ratio and increased arterial stiffness in apparently healthy individuals. Int J Clin Exp Med2015; 8(3): 4342–4348. eCollection 2015.
30.
NiroumandSKhajedalueeMKhadem-RezaiyanM, et al.Atherogenic index of plasma (AIP): a marker of cardiovascular disease. Med J Islam Repub Iran2015; 29: 240.
31.
LammerJZellerTHauseggerKA, et al.Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in superficial femoral artery occlusive disease). J Am Coll Cardiol2013; 62: 1320–1327.
